Zhejiang Jingxin Pharmaceutical (ZJXP HK): Synthetic Expert Call Transcript (21 Sep 2026)
The Stagnation of the Generic Core: Zhejiang Jingxin's core business is locked in structural stagnation, with total revenue dipping 2.14% in 2025...
88 Views
IPO Databook: Zhejiang Jingxin Pharmaceutical (002020 HK) - Sep 2026
Zhejiang Jingxin Pharmaceutical is a group focused on CNS, cardiovascular, and cerebrovascular diseases, generating revenue from drugs, APIs,...
108 Views
No more insights